Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations
Trends in Cancer · 2025-10 · 11 (10) · 934-965
DOI: 10.1016/j.trecan.2025.08.013 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2025-10. Verfasst von Saheed Oluwasina Oseni und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Electronic address: saheed.oseni@moffitt.o…. Hauptthemen laut MEDLINE: HLA Antigens, Neoplasms, Immunotherapy, Healthcare Disparities. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Moffitt Cancer Center, Dr Miriam and Sheldon G Adelson Medical Research Foundation.
Abstract (Originalsprache)
Human leukocyte antigen (HLA)-based immunotherapeutics, such as tebentafusp-tebn and afamitresgene autoleucel, have expanded the treatment options for HLA-A*02-positive patients with rare solid tumors such as uveal melanoma, synovial sarcoma, and myxoid liposarcoma. Unfortunately, many patients of European, Latino/Hispanic, African, Asian, and Native American ancestry who carry non-HLA-A*02 alleles remain largely ineligible for most current HLA-based immunotherapies. This comprehensive review introduces HLA allotype-driven cancer health disparities (HACHD) as an emerging research focus, and examines how past and current HLA-targeted immunotherapeutic strategies may have inadvertently contributed to cancer health disparities. We discuss several preclinical and clinical strategies, including the incorporation of artificial intelligence (AI), to address HACHD. Last, we emphasize the urgent need for further research to better understand HLA allotype heterogeneity and its influence on tumor immunopeptidome-driven immune responses. We anticipate that these strategies will accelerate the development and implementation of both personalized and broad-spectrum HLA-based immunotherapies, and will ultimately improve cancer treatment across genetically heterogeneous patient populations worldwide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Science, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Electronic address: saheed.oseni@moffitt.org.
- Department of Clinical Science, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
- Department of Clinical Science, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Electronic address: patrick.hwu@moffitt.org.
Förderung
- NCI NIH HHS
- Moffitt Cancer Center
- Dr Miriam and Sheldon G Adelson Medical Research Foundation
- Austin Medical Research Foundation
- National Institutes of Health National Cancer Institute
Zitieren
APA
Oseni, S. O., Wang, Y., & Hwu, P. (2025). Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations. Trends in Cancer, 11(10), 934-965. https://doi.org/10.1016/j.trecan.2025.08.013
Vancouver
Oseni SO, Wang Y, Hwu P. Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations. Trends in Cancer. 2025;11(10):934-965. doi:10.1016/j.trecan.2025.08.013
BibTeX
@article{Oseni2025,
author = {Oseni, Saheed Oluwasina and Wang, Yunfei and Hwu, Patrick},
title = {Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations},
journal = {Trends in Cancer},
year = {2025},
volume = {11},
number = {10},
pages = {934--965},
doi = {10.1016/j.trecan.2025.08.013}
}
EUVIMED